Alerts will be sent to your verified email
Verify Email
BETA
|
Beta Drugs
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.73 % | 8.81 % | 16.01 % |
|
5yr average Equity Multiplier
|
1.75 | 1.5 | 1.27 |
|
5yr Average Asset Turnover Ratio
|
1.04 | 0.79 | 1.09 |
|
5yr Avg Net Profit Margin
|
11.97 % | 7.78 % | 12.08 % |
|
Price to Book
|
0.0 | 4.92 | 6.74 |
|
P/E
|
43.74 | 29.23 | 26.59 |
|
5yr Avg Cash Conversion Cycle
|
15.7 Days | 84.02 Days | 2.39 Days |
|
Inventory Days
|
43.83 Days | 27.61 Days | 37.29 Days |
|
Days Receivable
|
87.61 Days | 123.89 Days | 15.63 Days |
|
Days Payable
|
113.94 Days | 93.18 Days | 59.94 Days |
|
5yr Average Interest Coverage Ratio
|
13.71 | 39.83 | 66.99 |
|
5yr Avg ROCE
|
27.85 % | 12.74 % | 18.99 % |
|
5yr Avg Operating Profit Margin
|
21.58 % | 9.47 % | 13.23 % |
|
5 yr average Debt to Equity
|
0.23 | 0.2 | 0.01 |
|
5yr CAGR Net Profit
|
31.07 % | 19.56 % | 26.54 % |
|
5yr Average Return on Assets
|
12.53 % | 5.89 % | 12.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 50.57 % | 67.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.02 % | 0.0 | -1.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beta Drugs
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|